Physician profile
Marrouf Azar
NPI 1467616433
$2,030.16
in general payments reported to CMS, 2019-2025
16 companies · $485 in 2025
The $485 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $89.95 · 2020: $113 · 2021: $120 · 2022: $92.84 · 2023: $461 · 2024: $668 · 2025: $485.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,506 · Education: $109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,505.92 |
| Education | $108.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $334.57 | 2020-2024 | Farxiga, Lokelma |
| Recor Medical INC | $295.10 | 2024 | Paradise Renal Denervation System |
| Alexion Pharmaceuticals, INC. | $254.80 | 2021-2025 | Soliris, Ultomiris |
| Ardelyx, INC. | $199.74 | 2023-2025 | Xphozah 30 Mg, Ibsrela |
| Otsuka America Pharmaceutical, INC. | $151.73 | 2022-2023 | Jynarque |
| Novo Nordisk INC | $144.63 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $141.69 | 2023-2025 | Tavneos, Krystexxa |
| Travere Therapeutics, INC. | $138.66 | 2023-2025 | |
| Vifor Pharma, INC. | $102.09 | 2019-2022 | |
| Calliditas Therapeutics US INC. | $65.92 | 2024-2025 | Tarpeyo |
| Novartis Pharmaceuticals Corporation | $49.97 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $43.76 | 2022-2024 | |
| Aurinia Pharma U.S., INC. | $36.66 | 2023-2025 | Lupkynis |
| Kyowa Kirin, INC. | $30.71 | 2024-2025 | Crysvita |
| Scpharmaceuticals INC. | $23.05 | 2025 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $17.08 | 2025 | Purified Cortrophin Gel |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marrouf Azar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.